Hwang, Jonathan K.
del Toro, Natalia Pelet
Han, George
Oh, Dennis H.
Tejasvi, Trilokraj
Lipner, Shari R. http://orcid.org/0000-0001-5913-9304
Article History
Accepted: 5 November 2023
First Online: 7 December 2023
Declarations
:
: No sources of funding were used for the preparation of this study/article.
: Jonathan K. Hwang, Natalia Pelet del Toro, and Dennis H. Oh have no conflicts of interest that are directly relevant to the content of this article. George Han reports honoraria or research grants from AbbVie, Amgen, Arcutis, Athenex, Bausch Health, Boehringer Ingelheim, Bond Avillion, Bristol Myers Squibb, Celgene Corporation, Dermavant, DermTech, Eli Lilly and Company, EPI Health, Janssen Pharmaceuticals, LEO Pharma, MC2 Therapeutics, Novartis, Ortho Dermatologics, PellePharm, Pfizer, Regeneron Pharmaceuticals, Sanofi Genzyme, SUN Pharmaceutical Industries Ltd, and UCB. Trilokraj Tejasvi serves on the board of the International Society of Teledermatology. Shari R. Lipner has served as a consultant for Eli Lilly, Ortho-Dermatologics, Belle Torus Corporation, and Moberg Pharmaceuticals.
: Institutional review board approval was not required for this study.
: Not applicable.
: Not applicable.
: All data supporting the findings of this article are available within this paper.
: Not applicable.
: JKH, NPT, GH, DHO, TT, and SRL have all made substantial contributions to aspects of the work. All authors have read and approved the final version.